Galectin Therapeutics GALT, the leading developer of therapeutics
that target galectin proteins to treat fibrosis and cancer, today announced
new preclinical data on the efficacy of anti-galectin therapy on diabetic
kidney disease. Treatment of diabetic mice with GR-MD-02 was found to reverse
the primary kidney disease associated with diabetes, called diabetic
nephropathy, the leading cause of kidney failure, dialysis and kidney
transplant. GR-MD-02 is the Company's lead galectin inhibitor in development
for the treatment of liver fibrosis, including non-alcoholic steatohepatitis
(NASH) liver disease.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in